Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cue Biopharma, Inc.CUE · Entity 6301 | CHIEF FINANCIAL OFFICER | March 21, 2025 | March 25, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cue Biopharma, Inc.
Report date March 21, 2025 · Filed March 25, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.99 · Expires 2035-03-20 | Direct | 200,000 |
Reported balance
After 2025-03-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-03-21 · Grant · Acquired 200,000 · Balance 200,000 F1: This stock option becomes exercisable in eight equal semi-annual installments beginning on September 21, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option becomes exercisable in eight equal semi-annual installments beginning on September 21, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 21, 2025 Filed Mar 25, 2025 20:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0000950170-25-044348 · ownership.xml · derivative · entry 1 Millar Kerri-Ann · CIK 0001739126 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2035-03-20 F1 · derivative.exercise_date: This stock option becomes exercisable in eight equal semi-annual installments beginning on September 21, 2025. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0000950170-24-070559 · ownership.xml · derivative · entry 1 Millar Kerri-Ann · CIK 0001739126 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2034-06-04 F1 · derivative.exercise_date: This stock option becomes exercisable in eight equal semi-annual installments beginning on December 5, 2024. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 21:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0000950170-24-028612 · ownership.xml · derivative · entry 1 Millar Kerri-Ann · CIK 0001739126 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2034-03-05 F1 · derivative.exercise_date: This stock option becomes exercisable in eight equal semi-annual installments beginning on September 6, 2024. Read SEC document |
| July 21, 2023 Filed Jul 25, 2023 16:31 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 113,000 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001209191-23-043277 · doc4.xml · derivative · entry 1 Millar Kerri-Ann · CIK 0001739126 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,000 Underlying: Common Stock · 113,000 shares Expires 2033-07-20 F1 · derivative.exercise_date: This stock option grant becomes exercisable in twenty four equal monthly installments beginning on August 21, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:58 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 124,000 | $0.00 Strike: $3.21 | $0.00 |
DisclosureSEC source: 0001209191-23-011245 · doc4.xml · derivative · entry 1 Millar Kerri-Ann · CIK 0001739126 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,000 Underlying: Common Stock · 124,000 shares Expires 2033-02-15 F1 · derivative.exercise_date: This stock option becomes exercisable in eight equal semi-annual installments beginning on August 16, 2023. Read SEC document |
| August 22, 2022 Filed Aug 23, 2022 20:03 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Tax withholdingCommon Stock | 2,828 | $3.05 | $8,625.40 |
DisclosureSEC source: 0001209191-22-047161 · doc4.xml · nonDerivative · entry 2 Millar Kerri-Ann · CIK 0001739126 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,311 Read SEC document |
| August 21, 2022 Filed Aug 23, 2022 20:03 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionRestricted Stock Units · Derivative | 6,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-047161 · doc4.xml · derivative · entry 3 Millar Kerri-Ann · CIK 0001739126 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit award represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: Represents a restricted stock unit award granted on August 21, 2020. The restricted stock units vest in three equal annual installments beginning on August 21, 2020. F3 · derivative.expiration_date: Represents a restricted stock unit award granted on August 21, 2020. The restricted stock units vest in three equal annual installments beginning on August 21, 2020. Read SEC document |
| August 21, 2022 Filed Aug 23, 2022 20:03 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionCommon Stock | 6,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-047161 · doc4.xml · nonDerivative · entry 1 Millar Kerri-Ann · CIK 0001739126 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,139 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award F1 · price: Represents shares of common stock received upon vesting of a restricted stock unit award Read SEC document |
| March 25, 2022 Filed Mar 29, 2022 20:05 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.01 | $0.00 |
DisclosureSEC source: 0001209191-22-021446 · doc4.xml · derivative · entry 2 Millar Kerri-Ann · CIK 0001739126 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-03-24 F2 · derivative.exercise_date: 2. This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 25, 2022. Read SEC document |
| February 09, 2022 Filed Mar 29, 2022 20:05 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $6.91 | $0.00 |
DisclosureSEC source: 0001209191-22-021446 · doc4.xml · derivative · entry 1 Millar Kerri-Ann · CIK 0001739126 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2032-02-08 F1 · derivative.exercise_date: 1. This stock option grant becomes exercisable in eight equal semi-annual installments beginning August 9, 2022. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 23:21 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionStock Option (right to buy) · Derivative | 1,251 | $0.00 Strike: $7.50 | $0.00 |
DisclosureSEC source: 0001209191-21-059698 · doc4.xml · derivative · entry 6 Millar Kerri-Ann · CIK 0001739126 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,749 Underlying: Common Stock · 1,251 shares Expires 2024-12-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2021. F6 · derivative.exercise_date: The option vests in eight equal semi-annual installments beginning March 25, 2018. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 23:21 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | SaleCommon Stock | 1,251 | $14.21 | $17,782.84 |
DisclosureSEC source: 0001209191-21-059698 · doc4.xml · nonDerivative · entry 4 Millar Kerri-Ann · CIK 0001739126 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,472 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.01 to $14.46, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 23:21 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionCommon Stock | 1,251 | $7.50 | $9,382.50 |
DisclosureSEC source: 0001209191-21-059698 · doc4.xml · nonDerivative · entry 3 Millar Kerri-Ann · CIK 0001739126 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,723 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2021. Read SEC document |
| August 23, 2021 Filed Oct 5, 2021 23:21 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionRestricted Stock Units · Derivative | 6,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-059698 · doc4.xml · derivative · entry 5 Millar Kerri-Ann · CIK 0001739126 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock · 6,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit award represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: Represents a restricted stock unit award granted on August 21, 2020. The restricted stock units vest in three equal annual installments beginning on August 21, 2020. F5 · derivative.expiration_date: Represents a restricted stock unit award granted on August 21, 2020. The restricted stock units vest in three equal annual installments beginning on August 21, 2020. Read SEC document |
| August 23, 2021 Filed Oct 5, 2021 23:21 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Tax withholdingCommon Stock | 1,961 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-059698 · doc4.xml · nonDerivative · entry 2 Millar Kerri-Ann · CIK 0001739126 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,472 Read SEC document |
| August 23, 2021 Filed Oct 5, 2021 23:21 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionCommon Stock | 6,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-059698 · doc4.xml · nonDerivative · entry 1 Millar Kerri-Ann · CIK 0001739126 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 22:43 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $15.55 | $0.00 |
DisclosureSEC source: 0000899243-21-006354 · doc4.xml · derivative · entry 1 Millar Kerri-Ann · CIK 0001739126 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2031-02-09 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning August 10, 2021. Read SEC document |
| August 24, 2020 Filed Aug 25, 2020 20:12 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Tax withholdingCommon Stock | 1,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-048212 · doc4.xml · nonDerivative · entry 2 Millar Kerri-Ann · CIK 0001739126 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,766 Read SEC document |
| August 21, 2020 Filed Aug 25, 2020 20:12 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionRestricted Stock Units · Derivative | 6,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-048212 · doc4.xml · derivative · entry 5 Millar Kerri-Ann · CIK 0001739126 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,334 Underlying: Common Stock · 6,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit award represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: Represents a restricted stock unit award granted on August 21, 2020. The restricted stock units vest in three equal annual installments beginning on August 21, 2020. F4 · derivative.expiration_date: Represents a restricted stock unit award granted on August 21, 2020. The restricted stock units vest in three equal annual installments beginning on August 21, 2020. Read SEC document |
| August 21, 2020 Filed Aug 25, 2020 20:12 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-048212 · doc4.xml · derivative · entry 4 Millar Kerri-Ann · CIK 0001739126 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit award represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: Represents a restricted stock unit award granted on August 21, 2020. The restricted stock units vest in three equal annual installments beginning on August 21, 2020. F4 · derivative.expiration_date: Represents a restricted stock unit award granted on August 21, 2020. The restricted stock units vest in three equal annual installments beginning on August 21, 2020. Read SEC document |
| August 21, 2020 Filed Aug 25, 2020 20:12 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $19.87 | $0.00 |
DisclosureSEC source: 0001209191-20-048212 · doc4.xml · derivative · entry 3 Millar Kerri-Ann · CIK 0001739126 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2030-08-21 F2 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning February 21, 2021. Read SEC document |
| August 21, 2020 Filed Aug 25, 2020 20:12 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionCommon Stock | 6,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-048212 · doc4.xml · nonDerivative · entry 1 Millar Kerri-Ann · CIK 0001739126 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| February 05, 2020 Filed Feb 12, 2020 21:52 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $16.26 | $0.00 |
DisclosureSEC source: 0001209191-20-008809 · doc4.xml · derivative · entry 1 Millar Kerri-Ann · CIK 0001739126 · VP-Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-02-05 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning August 5, 2020. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 21:09 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $6.42 | $0.00 |
DisclosureSEC source: 0001209191-19-018083 · doc4.xml · derivative · entry 2 Millar Kerri-Ann · CIK 0001739126 · VP-Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-03-06 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 6, 2019. Read SEC document |
| August 29, 2018 Filed Aug 29, 2018 22:39 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | PurchaseCommon Stock | 1,000 | $8.48 | $8,480.00 |
DisclosureSEC source: 0001209191-18-048862 · doc4.xml · nonDerivative · entry 1 Millar Kerri-Ann · CIK 0001739126 · VP-Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
| July 23, 2018 Filed Jul 25, 2018 20:50 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $11.54 | $0.00 |
DisclosureSEC source: 0001209191-18-043907 · doc4.xml · derivative · entry 1 Millar Kerri-Ann · CIK 0001739126 · VP-Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2025-07-23 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight semi-annual installments beginning July 23, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.